Data
Click on Protocol Number of interest to view study-related documentation or download data files.
(DTMC data files are under development.)
| Division | Study Number | Title | Investigator(s) | Release Date Sort ascending |
|---|---|---|---|---|
| CTN | NIDA-CTN-0051 | Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment | John Rotrosen, M.D. | Jan 12, 2018 |
| DTMC | NIDA-MDS-0003 | Phase I, Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Cocaine And Ethanol And Oral Disulfiram | John D. Roache, Ph.D. | Dec 21, 2017 |
| DTMC | NIDA-CPU-0008 | Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil | Reese Jones, M.D. | Dec 21, 2017 |
| DTMC | NIDA-CTO-0007 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Cabergoline For The Treatment Of Cocaine Dependence | Steven Shoptaw, Ph.D., Thomas F. Newton, M.D. | Dec 21, 2017 |
| DTMC | NIDA-CSP-1020 | A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal | Ann Montgomery, R.N. | Dec 21, 2017 |
| CTN | NIDA-CTN-0059 | The TAPS Tool: Screen and Brief Assessment Tool Validation Study | Robert P Schwartz, M.D., Li-Tzy Wu, Psy.D., Jennifer McNeely, M.D. | Sep 14, 2017 |
| CTN | NIDA-CTN-0056 | Testing and Linkage to HIV Care in China: A Cluster Randomized Trial | Zunyou Wu, MD, PhD | Sep 14, 2017 |
| DTMC | NIDA-CPU-0002 | Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers | Louis Cantilena, Jr., M.D, Ph.D. | May 23, 2017 |
| DTMC | NIDA-CPU-0005 | Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. | Louis Cantilena, Jr., M.D, Ph.D. | May 23, 2017 |
| DTMC | NIDA-CPU-0004 | Study of Interactions Between GBR 12909 and Cocaine | Kathryn Cunningham, Ph.D., John Grabowski, Ph.D. | May 23, 2017 |